内容紹介
Summary
It has been reported that docetaxel, cisplatin, and 5-FU combination chemotherapy(DCF)is effective for advanced esophageal cancer. However, we often encounter severe hematotoxicity during DCF therapy. Here, we retrospectively analyzed the data of patients with advanced esophageal cancer treated with DCF at our department, and assessed the efficacy of pegfilgrastim and the issues associated with its use. According to the results, pegfilgrastim may reduce the severe hematotoxicity associated with DCF therapy and may contribute to the maintenance of the intensity of DCF. However, neutropenia had already occurred before pegfilgrastim administration on day 7 in most patients. Therefore, the appropriate timing of pegfilgrastim administration in DCF must be determined in a future prospective study.
要旨
進行食道癌に対するDCF療法は高い奏効率を誇る一方,重篤な血液毒性を高頻度に認める。今回,当科でDCF療法を施行した進行食道癌を対象とし,血液毒性に対するペグフィルグラスチムの有効性と課題を後方視的に検討した。ペグフィルグラスチムの予防投与により好中球減少や化学療法の延期が抑制され,DCF療法の治療強度維持に寄与することが示唆された。一方で,ペグフィルグラスチム投与時すでに好中球減少を来している症例も散見され,適切な投与時期についてはさらなる検討を要する。
目次
It has been reported that docetaxel, cisplatin, and 5-FU combination chemotherapy(DCF)is effective for advanced esophageal cancer. However, we often encounter severe hematotoxicity during DCF therapy. Here, we retrospectively analyzed the data of patients with advanced esophageal cancer treated with DCF at our department, and assessed the efficacy of pegfilgrastim and the issues associated with its use. According to the results, pegfilgrastim may reduce the severe hematotoxicity associated with DCF therapy and may contribute to the maintenance of the intensity of DCF. However, neutropenia had already occurred before pegfilgrastim administration on day 7 in most patients. Therefore, the appropriate timing of pegfilgrastim administration in DCF must be determined in a future prospective study.
要旨
進行食道癌に対するDCF療法は高い奏効率を誇る一方,重篤な血液毒性を高頻度に認める。今回,当科でDCF療法を施行した進行食道癌を対象とし,血液毒性に対するペグフィルグラスチムの有効性と課題を後方視的に検討した。ペグフィルグラスチムの予防投与により好中球減少や化学療法の延期が抑制され,DCF療法の治療強度維持に寄与することが示唆された。一方で,ペグフィルグラスチム投与時すでに好中球減少を来している症例も散見され,適切な投与時期についてはさらなる検討を要する。